Congress ticker disclosure profile

As of July 21 at 4:32 AM EDT

Public STOCK Act rows mentioning

XLF

A factual page for public Congressional disclosures that reference XLF. Veridion shows filed rows, disclosed amount ranges, dates, and source links. It does not imply motive or wrongdoing.

90d rows

0

Feed lifetime

38

Member filers

5

Disclosed ranges

$978K

Most active member desks

32 buys vs 6 sells

Thomas Macarthur28

Republican · House · 3.0

Carlos Curbelo4

Republican · House · 26.0

E. Scott Rigell3

Republican · House · 2.0

David Cheston Rouzer2

Republican · House · NC-7.0

Deborah K. Ross1

Democrat · House · NC-2.0

Latest source-stamped receipts

Latest trade Jan 4, 2021

DateMemberActionAmountFiledReceipt
Jan 4, 2021Deborah K. RossBuyReceipt pending ingestionJan 24, 2021Receipt pending ingestion
Sep 2, 2020David Cheston RouzerSellReceipt pending ingestionSep 28, 2020Receipt pending ingestion
Sep 2, 2020David Cheston RouzerSell$1,001 to $15,000Sep 28, 2020Open card
Dec 26, 2018Thomas MacarthurBuyReceipt pending ingestionJan 11, 2019Receipt pending ingestion
Dec 26, 2018Thomas MacarthurBuy$15,001 to $50,000Jan 11, 2019Open card
Sep 26, 2018Thomas MacarthurBuyReceipt pending ingestionOct 6, 2018Receipt pending ingestion
Sep 26, 2018Thomas MacarthurBuy$1,001 to $15,000Oct 6, 2018Open card
Jun 20, 2018Thomas MacarthurBuyReceipt pending ingestionJul 10, 2018Receipt pending ingestion
Jun 20, 2018Thomas MacarthurBuy$1,001 to $15,000Jul 10, 2018Open card
May 11, 2018Thomas MacarthurSellReceipt pending ingestionJun 5, 2018Receipt pending ingestion
May 11, 2018Thomas MacarthurSell$15,001 to $50,000Jun 5, 2018Open card
Apr 18, 2018Thomas MacarthurBuyReceipt pending ingestionMay 10, 2018Receipt pending ingestion
Apr 18, 2018Thomas MacarthurBuy$15,001 to $50,000May 10, 2018Open card
Apr 6, 2018Carlos CurbeloSellReceipt pending ingestionAug 2, 2018Receipt pending ingestion
Apr 6, 2018Carlos CurbeloSell$1,001 to $15,000Aug 2, 2018Open card
Mar 21, 2018Thomas MacarthurBuyReceipt pending ingestionApr 9, 2018Receipt pending ingestion
Mar 21, 2018Thomas MacarthurBuy$1,001 to $15,000Apr 9, 2018Open card
Jan 22, 2018Carlos CurbeloBuyReceipt pending ingestionFeb 5, 2018Receipt pending ingestion
Jan 22, 2018Carlos CurbeloBuy$1,001 to $15,000Feb 5, 2018Open card
Jan 8, 2018Thomas MacarthurBuyReceipt pending ingestionFeb 5, 2018Receipt pending ingestion
Jan 8, 2018Thomas MacarthurBuy$100,001 to $250,000Feb 5, 2018Open card
Dec 26, 2017Thomas MacarthurBuyReceipt pending ingestionJan 10, 2018Receipt pending ingestion
Dec 26, 2017Thomas MacarthurBuy$1,001 to $15,000Jan 10, 2018Open card
Sep 25, 2017Thomas MacarthurBuyReceipt pending ingestionOct 8, 2017Receipt pending ingestion
Sep 25, 2017Thomas MacarthurBuy$1,001 to $15,000Oct 8, 2017Open card
Jul 28, 2017Thomas MacarthurBuyReceipt pending ingestionAug 3, 2017Receipt pending ingestion
Jul 28, 2017Thomas MacarthurBuy$50,001 to $100,000Aug 3, 2017Open card
Jun 26, 2017Thomas MacarthurBuyReceipt pending ingestionJul 9, 2017Receipt pending ingestion
Jun 26, 2017Thomas MacarthurBuy$1,001 to $15,000Jul 9, 2017Open card
Mar 27, 2017Thomas MacarthurBuyReceipt pending ingestionApr 9, 2017Receipt pending ingestion
Mar 27, 2017Thomas MacarthurBuy$1,001 to $15,000Apr 9, 2017Open card
Jan 17, 2017Thomas MacarthurBuyReceipt pending ingestionFeb 8, 2017Receipt pending ingestion
Jan 17, 2017Thomas MacarthurBuy$100,001 to $250,000Feb 8, 2017Open card
Jan 12, 2017Thomas MacarthurBuyReceipt pending ingestionFeb 8, 2017Receipt pending ingestion
Jan 12, 2017Thomas MacarthurBuy$250,001 to $500,000Feb 8, 2017Open card
Dec 13, 2016E. Scott RigellBuyReceipt pending ingestionJan 25, 2017Receipt pending ingestion
Dec 12, 2016E. Scott RigellBuyReceipt pending ingestionJan 25, 2017Receipt pending ingestion
Nov 30, 2016E. Scott RigellBuyReceipt pending ingestionDec 23, 2016Receipt pending ingestion

Source creed

This page is assembled from public STOCK Act disclosure records in the Veridion warehouse. 17 of 38 filed rows include disclosed amount ranges (45%). Rows without ranges stay labeled. Identification only; it does not imply motive or wrongdoing.

Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.